Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturers of vaginal contraceptives "encouraged" to evaluate STD prevention.

This article was originally published in The Tan Sheet

Executive Summary

OTC VAGINAL CONTRACEPTIVE MANUFACTURERS "ENCOURAGED" TO EVALUATE STD (sexually transmitted disease) prevention in the Feb. 3 tentative final monograph on the product class. The TFM states that FDA "strongly encourages manufacturers to evaluate these products for use in the prevention of infectious diseases" because the "identification of safe and effective products to prevent the transmission of HIV and other STDs is a high-priority health concern."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel